ATLASXOMICS INC

ATLASXOMICS INC. specializes in advanced biotechnology research and development, focusing on molecular and cellular innovation outside the scope of nanobiotechnology. The company delivers scientific solutions grounded in experimental design, data-driven discovery, and translational biology, supporting the development of novel therapeutic platforms, diagnostic assays, and biological characterization methods. Their technical expertise includes high-throughput screening, genomic data analysis, protein engineering, and preclinical validation workflows, with an emphasis on reproducible, scalable research outcomes aligned with federal biomedical priorities. Differentiators include rigorous experimental methodology, domain-specific bioinformatics integration, and a focus on accelerating early-stage biotech innovation for public health applications. The contractor maintains a consistent relationship with the Department of Health and Human Services, providing R&D services that support agency missions in biomedical innovation, public health preparedness, and life sciences advancement. Work performed under HHS contracts centers on foundational biotechnology research, often in support of NIH or CDC initiatives, indicating a pattern of engagement in grant-funded, mission-critical scientific programs requiring high technical precision and regulatory alignment. ATLASXOMICS INC. operates primarily within NAICS 541714, which encompasses non-nano biotech R&D—spanning gene therapy vectors, recombinant protein development, cell line engineering, and biomarker discovery. This positions the company as a niche provider in the federal biotech ecosystem, serving agencies seeking non-clinical, pre-IND-stage scientific advancement rather than commercial product development. Their market focus is on foundational science that bridges academic discovery and applied federal health programs. As a small business entity structured as a 2L, ATLASXOMICS INC. is headquartered in New Haven, Connecticut, leveraging proximity to academic and biomedical research hubs. The company holds no federal certifications, but its consistent engagement with HHS demonstrates credibility in meeting stringent government research standards. Its geographic and operational profile reflects a focused, science-driven organization aligned with the federal biotechnology innovation pipeline.